GlassScriptPhysician profile
Bernadette E Whitaker
NPI 1881788248
$4,798.22
in general payments reported to CMS, 2019-2025
24 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.85 · 2023: $1,631 · 2024: $2,060 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,686.22 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.99 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $782.53 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $483.33 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $417.97 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $366.35 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $291.72 | 2023-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $255.29 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $242.48 | 2023-2024 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $207.18 | 2023-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $185.16 | 2023-2024 | Quviviq |
| Lundbeck LLC | $160.75 | 2023-2024 | Rexulti |
| Bausch Health US, LLC | $108.63 | 2023-2025 | Aplenzin, Wellbutrin |
| Biogen, INC. | $95.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $81.12 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $59.78 | 2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $52.01 | 2024-2025 | Xelstrym |
| Harmony Biosciences LLC | $31.94 | 2024 | |
| Collegium Pharmaceutical, INC. | $27.25 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $22.83 | 2024 | Xelstrym |
| Validus Pharmaceuticals LLC | $21.33 | 2024 | Equetro |
| Sage Therapeutics, LLC | $20.18 | 2025 | Zurzuvae |
| Indivior INC. | $19.85 | 2023 | Perseris |
| Neos Therapeutics, LP | $18.65 | 2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $16.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.